

Blue Dental_{sm}

17th Annual Oral Health Forum June 14, 2019 Amy Miller, Dental Product Sales Director

BlueCross BlueShield of South Carolina is an independent licensee of the Blue Cross and Blue Shield Association.

2019 Oral Health Actions, Initiatives and Desired Results

Actions

- D0411 and D0412 were added under preventive services effective 01/01/19
- Presented Medical-Dental Integration capabilities and value to brokers, agents and group leaders
- Assessment of current oral health needs of our members

Initiatives

- Member Messaging and Outreach
- Collaboration with other BCBS plans regarding Oral Health initiatives as well as data
- Medical-Dental Integration messaging in RFP's, renewals to groups (medical only)

Desired Results

- Increase the utilization of preventive services for at risk oral health members i.e. diabetes, cardiac, etc.
- Demonstrating the value of medicaldental integration to groups without dental with their current medical carrier it will shift to a medicaldental integration approach (one carrier) for their employees

Oral Health = Overall Health

Opioid Approach/Initiatives

- In July 2018, BCBS of SC partnered with the South Carolina Hospital Association and South Carolina Medical Association to form an *Opioid Risk Prevention Partnership (ORPP)*, which is designed to advance the conversation among and between hospitals, physicians and other providers, patients and the general public around the issues of pain and the appropriate use of alternatives to opioids in pain management.
- Mandatory registration and utilization of the South Carolina Reporting and Identification Prescription Tracking System (SCRIPTS) for all opioid prescribers.
 Providers must maintain documentation that the SCRIPTS database was verified before the issuance of a Schedule II through IV controlled substance prescription. This documentation may take the form of a notation in the member's medical record. If a provider's electronic medical record (EMR) automatically downloads SCRIPTS data and makes that available to the provider at the point of care, a notation for each patient is not required.
- D9613 infiltration of sustained-release therapeutic drug (single or multiple sites) or Exparel was added as a covered benefit effective 01.01.19 under Class III services.



